ONC Overview

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BeOne Medicines AG revenue for the last quarter amounts to 1.41B USD, increased 41.00

BeOne Medicines AG. EPS for the last quarter amounts to 0.08 USD, decreased -188.89

BeOne Medicines AG (ONC) has 11000 emplpoyees as of March 11 2026.

Today ONC has the market capitalization of 33.88B USD.